Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia

Nationwide Children's Hospital

Status: Completed

Conditions: Cystic Fibrosis

Treatments: Diagnostic Test: Capillary CO2 (CapCO2); Other: End tidal CO2 (EtCO2); Diagnostic Test: Arterial blood gas (ABG); Device: Transcutaneous CO2 (TCO2)

Study type: Interventional

Funder types: Other

Identifiers

NCT03734822

IRB15-00797

Details and patient eligibility

About

Four methods are routinely used to monitor CO2 in patients. End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia. CO2 is also monitored in other healthcare settings transcutaneously (TCO2), via finger stick capillary CO2 (CapCO2), and arterial blood gas (ABG). The purpose of this study is to perform all four measurements simultaneously during general anesthesia to identify which measure provides the most accurate data with the least amount of patient risk.

Enrollment: 47 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60 mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype)
• Hemodynamically stable undergoing general anesthesia for a scheduled procedure

Exclusion criteria

• Patients not diagnosed with CF
• CF patients undergoing anesthesia for emergency procedures

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

47 participants in 1 patient group

CF

Other group

Description:

Cystic fibrosis patients undergoing general anesthesia.

Treatment:

Diagnostic Test: Capillary CO2 (CapCO2)

Device: Transcutaneous CO2 (TCO2)

Other: End tidal CO2 (EtCO2)

Diagnostic Test: Arterial blood gas (ABG)